Skip to main content
OLIPASS CORPORATION logo

OLIPASS CORPORATION — Investor Relations & Filings

Ticker · 244460 ISIN · KR7244460002 KO Professional, scientific and technical activities
Open in API
Filings indexed 507 across all filing types
Latest filing 2026-06-05 Legal Proceedings Report
Country KR South Korea
Listing KO 244460

About OLIPASS CORPORATION

https://www.olipass.com/front/eng/index…

OLIPASS CORPORATION is a research and development company focused on creating RNA therapeutics. The company's core activities are centered on its proprietary OliPass Peptide Nucleic Acid (OPNA) platform. OPNA is a novel technology derived from Peptide Nucleic Acid (PNA) by introducing a cationic lipid moiety onto the nucleobase. This structural modification is designed to markedly improve cell permeability, a key challenge in nucleic acid-based drug delivery. The platform is optimized to induce exon skipping by specifically binding to target pre-mRNA inside the cell nucleus, enabling the discovery and development of new therapeutic candidates.

Recent filings

Filing Released Lang Actions
회생절차개시결정
Legal Proceedings Report Classification · 85% confidence The document is a court decision notice declaring the commencement of corporate rehabilitation (insolvency) proceedings for the company. It contains legal dates, court jurisdiction, and procedural details rather than financial statements or management discussion. This clearly falls under updates on significant legal matters of the company, matching the Legal Proceedings Report category.
2026-06-05 Korean
기타시장안내 (회생절차 개시결정 관련 시장안내)
Regulatory Filings Classification · 87% confidence The document is a Korean stock exchange "기타시장안내" (Other Market Notice) informing investors about the commencement of rehabilitation proceedings and suspension of a delisting process. It is a routine regulatory announcement with no actual financial statements, call transcript, report attachments, or proxy materials. It does not fit into specialized categories like Annual Report, Earnings Release, Delisting Announcement (the delisting itself is stayed), or M&A. Therefore, it is a general regulatory filing under "Regulatory Filings" (RNS).
2026-06-05 Korean
[기재정정]투자판단관련주요경영사항 (OliPass PNA 플랫폼 기술 기반 희귀질환 치료제 및 면역항암제 관련 치료제 개발을 위한 Vanda 제약과 신약 공동연구개발 계약 체결)
Regulatory Filings Classification · 58% confidence The document is a Korean stock exchange disclosure (“투자판단 관련 주요경영사항”) reporting a correction to a prior announcement about a joint R&D contract with Vanda Pharmaceuticals. It is not an earnings release, financing notice, proxy statement, management change, or formal report like an annual/interim report. Rather, it is a general regulatory announcement submitted to the exchange, so it falls under the fallback category Regulatory Filings (RNS).
2026-06-01 Korean
[기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령)
Regulatory Filings Classification · 80% confidence The document is a Korean regulatory ‘투자판단 관련 주요경영사항’ (material event) correction notice, describing the receipt of R&D funding and amendment of previously undisclosed amount. It is not an annual or interim report, dividend notice, management change, M&A, or financial statement, but a routine material event disclosure on the exchange. It therefore falls into the fallback category Regulatory Filings (RNS).
2026-06-01 Korean
[기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령)
Regulatory Filings Classification · 94% confidence The document is a Korean stock exchange disclosure titled “투자판단 관련 주요경영사항” (Investment Judgment Related Major Business Matters) with a correction notice. It is a routine corporate disclosure on the receipt of R&D funds, not a financial report, management discussion, or any other specialized category. This fits the general regulatory announcement category (Regulatory Filings).
2026-06-01 Korean
[기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령)
Regulatory Filings Classification · 75% confidence The document is a Korean stock exchange disclosure (‘투자판단 관련 주요경영사항’) regarding receipt of R&D funding and a subsequent correction (‘정정신고’), rather than a full financial report, earnings release, or management change. It is a routine material event notice under regulatory requirements, fitting the fallback “Regulatory Filings” category.
2026-06-01 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.